Bruins FM, Bronckers IMGJ, Groenewoud HMM, et al. - Researchers sought to determine the association between the degree of psoriasis improvement (as measured by the Psoriasis Area Severity Index [PASI] and body surface area [BSA] response) and quality of life (QOL; as measured by the Children’s Dermatology Life Quality Index [CDLQI]) in pediatric psoriasis. Further, they examined how treatment type associated with QOL, independent of psoriasis improvement. From the Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry), they extracted data of 319 children (aged < 18 years) with psoriasis who attended the outpatient clinic of the Department of Dermatology at the Radboud University Medical Center in Nijmegen, the Netherlands, between September 3, 2008, and May 4, 2018. The analysis revealed the highest improvements in QOL in correlation to a reduction of 90% or greater of the Psoriasis Area Severity Index, a reduction of 90% or greater in body surface area, and with systemic treatments. The Psoriasis Area Severity Index response did not affect the correlation between systemic therapy and improvement in QOL.